Compare Moderna, Inc. (MRNA) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Simon Property Group Inc — how do they compare? Moderna, Inc. trades at $136.79 (market cap $54.14B), while Simon Property Group Inc trades at $206.11 (market cap $66.18B). The key difference: Simon Property Group Inc is the larger of the two by market cap, and Simon Property Group Inc pays a 4.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SPG | |
|---|---|---|
Market Cap | $54.14B | $66.18B |
Sector | Health | Real Estate |
52-Week High | $174.38 | $236.70 |
52-Week Low | $22.36 | $173.35 |
Enterprise Value | $50.29B | $94.63B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
SPG trades at $211.88, up 1.17% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a Q2 2026 revenue increase of 19.3% and a net income margin of 66.57%, supported by a P/E of 14.95. Recent news includes a $800 million senior notes issuance and the launch of Simon Media Network to monetize mall traffic.
The outlook is mixed; analyst consensus targets $231.82 with 42% buy ratings, but technical indicators suggest near-term pressure. Key risks include high leverage with $24.21B long-term debt and sensitivity to retail real estate cycles. Upside potential hinges on continued leasing strength and effective new media initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
